JPRN-jRCT2041220034招募中1 期
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination in Subjects with KRAS G12C Mutant Advanced Solid Tumors
Yasuhiro Koh0 个研究点目标入组 3 人开始时间: 2022年6月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •For all participants:
- •- Has measurable disease by RECIST 1.1 criteria
- •- Has adequate organ function
- •- Male participants must be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception unless confirmed to be azoospermic
- •- Female participants must not be pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child-bearing potential (WOCBP); is a WOCBP and uses a contraceptive method that is highly effective, with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle and must have a negative highly sensitive pregnancy test within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention
- •For Arm 1 - Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease
- •- Has an untreated metastatic non-small cell lung cancer (NSCLC) with histologically OR blood-based confirmation of KRAS G12C mutation and histologic confirmation of programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) >=1%
- •- Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically or blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease
- •Expansion Group A: 3L/4L metastatic colorectal cancer (mCRC)
- •- Has histologically or cytologically confirmed diagnosis of unresectable and metastatic colorectal adenocarcinoma with histological or blood-based confirmation of KRAS G12C mutation
- •- Previous treatment failure of 2 or 3 previous lines of systemic therapy
- •Expansion Group B
- •- Has locally advanced unresectable or metastatic solid-tumor malignancy, excluding NSCLC or CRC, with histologically or blood- based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease
- •Arm 4 only - Has an untreated advanced or metastatic nonsquamous NSCLC with histologically or blood-based confirmation of KRAS G12C mutation
- •- Histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic colorectal adenocarcinoma and with histologically or blood-based confirmation of KRAS G12C mutation
- •- Previous treatment failure of one or 2 previous line(s) of systemic therapy
- •- Untreated locally advanced unresectable or metastatic colorectal adenocarcinoma with histologically or blood-based confirmation of KRAS G12C mutation
排除标准
- •- Has received chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation)
- •- Has a history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years
- •- Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis
- •- Has an active infection requiring systemic therapy
- •- Known history of HIV infection or. has a known history of Hepatitis B virus or known active Hepatitis C virus
- •- Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- •- Has a history of interstitial lung disease, noninfectious pneumonitis requiring active steroid therapy, or ongoing pneumonitis
- •- Has an active autoimmune disease requiring systemic therapy
- •- Has not fully recovered from any effects of major surgical procedure without significant detectable infection
- •- Has one or more of the following ophthalmological findings/conditions: intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma; diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and/or a diagnosis of retinal degenerative disease
- •- Has received live or live-attenuated vaccine within 4 weeks of study start
- •- Is unable to interrupt aspirin or other nonsteroidal anti-inflammatories (NSAIDs), other than an aspirin dose >=1.3 grams per day, for at least 2 days (5 days for long-acting agents [for example, piroxicam]) before, during, and for at least 2 days after administration of pemetrexed.
- •- Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone.
研究者
相似试验
未知
1 期
A Phase 1, Open-Label, Multi-center Study to Assess the Safety and Tolerability of AZD6244 (Selumetinib, ARRY142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)Inoperable Locally Advanced or Metastatic Biliary Tract CancerJPRN-jRCT2080222349AstraZeneca
已完成
不适用
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination with Palbociclib in Women with Estrogen Receptor Positive, HER2-Negative Advanced Breast CancerAdvanced Breast CancerNL-OMON50738G1 Therapeutics Inc.45
招募中
不适用
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumors / Terminal cancer10027655NL-OMON51516Merck Sharp & Dohme (MSD)30
未知
1 期
A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1152 in Japanese Patients With Acute Myeloid LeukaemiaAcute Myeloid LeukaemiaJPRN-jRCT2080220498AstraZeneca
已完成
1 期
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 uUnder Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.Advanced Solid Malignancy, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial CancerJPRN-jRCT2080222792AstraZeneca KK25